Publications

563 Publications Available
June 11, 2020
Blood

Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.

June 01, 2020
Nature Chemical Biology

Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.

May 12, 2020
Nat Commun.

UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.

May 08, 2020
Nat Commun.

p85β regulatory subunit of phosphatidylinositol 3-kinase upregulates tyrosine kinase, AXL, activating p110 subunit to induce PDK1/SGK3 signaling in PIK3R2-amplified ovarian cancer. These findings indicate that targeting AXL with small molecule inhibitors could be a potential therapeutic strategy.

May 04, 2020
Leukemia

Scientists discovered point mutations in the ErbB2 receptor in a small subset of hematologic malignancies. These point mutations are shown to be oncogenic in cytokine-independent cellular assay and sensitive to irreversible ErbB inhibitors.

May 01, 2020
JCO Clin Cancer Inform.

TransPRECISE, a cancer-specific integrated network estimation model, assesses pathway similarities between patients and cell lines at a sample-specific level. This framework bridges the gap and could be used to identify appropriate preclinical models for prioritizing specific drug targets.

April 14, 2020
Cell Reports

Integrated analyses of multi-omics data indicate molecular and cellular differences in the clinical subtypes of high-grade serous ovarian cancer.

April 01, 2020
JCO Clin Cancer Inform.

Protein dependency analytic module integrated in TCPA measures key cancer dependencies in a context dependent manner. This analysis suggests that protein expression data are a highly valuable information resource for understanding tumor vulnerabilities and identifying therapeutic opportunities.

April 01, 2020
Translational Oncology

In vitro and in vivo studies conducted by CTD2 scientists at Emory University demonstrate that combination of JNK inhibitor, AS602801 with androgen receptor inhibitor, enzalutamide synergistically inhibit proliferation, migration, invasion, and prevent tumor growth in prostate cancer.

March 24, 2020
Nature Communications

Chemical biology approach reveals metabolic heterogeneity in cellular subtypes. This study suggests targeting both glucose reporter 1 and pyruvate dehydrogenase, components of glycolysis and mitochondrial metabolism, inhibit cancer cell invasion.

Pages

CSV

.